Lyell Immunopharma, Inc.LYELNASDAQ
Loading
Year-over-year operating cash flow growth rate
Latest
-112.86%
↓ 604% vs avg
Percentile
P4
Near historical low
Streak
2 qtr
Consecutive declineDecelerating
Average
-16.04%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | -112.86% |
| Q3 2025 | 17.07% |
| Q2 2025 | 37.05% |
| Q1 2025 | -15.87% |
| Q4 2024 | -34.82% |
| Q3 2024 | 8.01% |
| Q2 2024 | 9.33% |
| Q1 2024 | -3.40% |
| Q4 2023 | -7.83% |
| Q3 2023 | 3.77% |
| Q2 2023 | 15.26% |
| Q1 2023 | -14.76% |
| Q4 2022 | -8.53% |
| Q3 2022 | 16.31% |
| Q2 2022 | 7.35% |
| Q1 2022 | -44.25% |
| Q4 2021 | -30.13% |
| Q3 2021 | 24.91% |
| Q2 2021 | -1.04% |
| Q1 2021 | -25.68% |
| Q4 2020 | -23.60% |
| Q3 2020 | 75.68% |
| Q2 2020 | -276.92% |
| Q1 2020 | 0.00% |